Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Genomic Rearrangements Define Lineage Relationships between Adjacent Lepidic and Invasive Components in Lung Adenocarcinoma
Wigle, Dennis A. , Lima, Joema Felipe , Harris, Faye R. , Johnson, Sarah H. , Halling, Geoffrey C. , Seto, C, Terra, Simone , Kosari, Farhad , Peikert, Tobias, Aubry, Marie-Christine, Vasmatzis, George , Halling, Geoffrey, Asiedu, Michael K. , Seto, Charlie T, Murphy, Stephen J. , Yang, Ping

Mayo Clinic

Cancer Research | May 30, 2014 | Volume: 74 | Issue: 11 | Pages: 3157-3167

10.1158/0008-5472.can-13-1727 | PMID 24879567 Get It

AbstractThe development of adenocarcinoma of the lung is believed to proceed from in situ disease (adenocarcinoma in situ, AIS) to minimally invasive disease with prominent lepidic growth (minimally invasive adenocarcinoma, MIA), then to fully invasive adenocarcinoma (AD), but direct evidence for this model has been lacking. Because some lung adenocarcinomas show prominent lepidic growth (AD-L), we designed a study to address the lineage relationship between the lepidic (noninvasive) component (L) and the adjacent nonlepidic growth component representing invasive disease within individual tumors. Lineage relationships were evaluated by next-generation DNA sequencing to define large genomic rearrangements in microdissected tissue specimens collected by laser capture. We found a strong lineage relationship between the majority of adjacent lepidic and invasive components, supporting a putative AIS–AD transition. Notably, many rearrangements were detected in the less aggressive lepidic component, although the invasive component exhibited an overall higher rate of genomic rearrangement. Furthermore, a significant number of genomic rearrangements were present in histologically normal lung adjacent to tumor, but not in host germline DNA, suggesting field defects restricted to zonal regions near a tumor. Our results offer a perspective on the genetic pathogenesis underlying adenocarcinoma development and its clinical management. Cancer Res; 74(11); 3157–67. ©2014 AACR.
An investigation into false‐negative transthoracic fine needle aspiration and core biopsy specimens
Minot, Douglas M., Gilman, Elizabeth A. , Aubry, Marie‐Christine, Voss, Jesse S. , Epps, Sarah G. Van, Tuve, Delores J, Sciallis, Andrew P. , Henry, Michael , Salomão, Diva R. , Carlson, Stephanie K., Clayton, Amy C., Aubry, Marie-Christine, Lee, Peter

Mayo Clinic

Diagnostic Cytopathology | May 28, 2014 | Volume: 42 | Issue: 12 | Pages: 1063-1068

10.1002/dc.23169 | PMID 24866385 Get It

Transthoracic fine needle aspiration (TFNA)/core needle biopsy (CNB) under computed tomography (CT) guidance has proved useful in the assessment of pulmonary nodules. We sought to determine the TFNA false‐negative (FN) rate at our institution and identify potential causes of FN diagnoses. Medical records were reviewed from 1,043 consecutive patients who underwent CT‐guided TFNA with or without CNB of lung nodules over a 5‐year time period (2003–2007). Thirty‐seven FN cases of “negative” TFNA/CNB with malignant outcome were identified with 36 cases available for review, of which 35 had a corresponding CNB. Cases were reviewed independently (blinded to original diagnosis) by three pathologists with 15 age‐ and sex‐matched positive and negative controls. Diagnosis (i.e., nondiagnostic, negative or positive for malignancy, atypical or suspicious) and qualitative assessments were recorded. Consensus diagnosis was suspicious or positive in 10 (28%) of 36 TFNA cases and suspicious in 1 (3%) of 35 CNB cases, indicating potential interpretive errors. Of the 11 interpretive errors (including both suspicious and positive cases), 8 were adenocarcinomas, 1 squamous cell carcinoma, 1 metastatic renal cell carcinoma, and 1 lymphoma. The remaining 25 FN cases (69.4%) were considered sampling errors and consisted of 7 adenocarcinomas, 3 nonsmall cell carcinomas, 3 lymphomas, 2 squamous cell carcinomas, and 2 renal cell carcinomas. Interpretive and sampling error cases were more likely to abut the pleura, while histopathologically, they tended to be necrotic and air‐dried. The overall FN rate in this patient cohort is 3.5% (1.1% interpretive and 2.4% sampling errors). Diagn. Cytopathol. 2014;42:1063–1068;. © 2014 Wiley Periodicals, Inc.
AQP4 autoantibody assay performance in clinical laboratory service
Fryer, J.P. , Lennon, Vanda A. , Pittock, Sean J. , Jenkins, Sarah M. , Fallier‐Becker, Petra, Clardy, Stacey , Horta, Erika , Jedynak, E.A., Lucchinetti, Claudia F. , Shuster, Elizabeth A., Weinshenker, Brian G. , Wingerchuk, Dean M. , McKeon, Andrew , Pittock, S J , Weinshenker, Brian G , McKeon, Andrew , Clardy, Stacey L

Mayo Clinic

Neurology Neuroimmunology & Neuroinflammation | May 23, 2014 | Volume: 1 | Issue: 1 | Pages: No page available

10.1212/nxi.0000000000000011 | PMID 25340055 Get It

Sarcopenia in patients with bladder cancer undergoing radical cystectomy: Impact on cancer‐specific and all‐cause mortality
Psutka, Sarah P. , Carrasco, Alonso , Schmit, Grant D. , Moynagh, Michael R., Boorjian, Stephen A. , Frank, Igor, Stewart, Suzanne, Thapa, Prabin , Tarrell, Robert F., Cheville, John C. , Tollefson, Matthew K. , Psutka, Sarah P

Mayo Clinic

Cancer | May 19, 2014 | Volume: 120 | Issue: 18 | Pages: 2910-2918

10.1002/cncr.28798 | PMID 24840856 Get It

BACKGROUNDThe authors evaluated sarcopenia as a predictor of cancer‐specific survival (CSS) and overall survival (OS) among patients with urothelial cancer of the bladder undergoing radical cystectomy (RC).METHODSThe lumbar skeletal muscle index (SMI) of 205 patients treated with RC for urothelial cancer between 2000 and 2007 was measured. Sarcopenia was classified according to international consensus definitions (SMI of < 55 cm2/m2 for men and < 39 cm2/m2 for women). The CSS and OS were estimated using the Kaplan‐Meier method and compared with the log‐rank test. Variables associated with CSS and all‐cause mortality were summarized with hazard ratios (HRs).RESULTSOf 205 patients, 141 (68.8%) were sarcopenic. Patients with sarcopenia were older, but were otherwise similar to patients without sarcopenia with respect to sex, Charlson comorbidity index, American Society of Anesthesiologists score, Eastern Cooperative Oncology Group performance status, receipt of neoadjuvant chemotherapy, TNM stage of disease, and tumor grade (P > .05 for all). The median follow‐up was 6.7 years, during which time 135 patients died, including 91 who died of bladder cancer. Sarcopenic patients had significantly worse 5‐year CSS (49% vs 72%; P = .003) and OS (39% vs 70%; P = .003) compared with patients without sarcopenia. Moreover, sarcopenia was found to be independently associated with both increased CSS (HR, 2.14; P = .007) and all‐cause mortality (HR, 1.93; P = .004) on multivariable analysis.CONCLUSIONSThe presence of sarcopenia was found to significantly increase a patient's risk of CSS and all‐cause mortality after undergoing RC for bladder cancer. Cancer 2014;120:2910–2918. © 2014 American Cancer Society.
Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study
Grothey, Axel, Flick, E. Dawn, Cohn, Allen Lee, Bekaii‐Saab, Tanios , Bendell, Johanna C. , Kozloff, Mark, Roach, Nancy, Mun, Yong, Fish, Susan, Hurwitz, Herbert I. , Bekaii-Saab, Tanios S

Mayo Clinic

Pharmacoepidemiology and Drug Safety | May 16, 2014 | Volume: 23 | Issue: 7 | Pages: 726-734

10.1002/pds.3633 | PMID 24830357 Get It

ABSTRACTPurposeThis analysis from Avastin® Registries: Investigation of Effectiveness and Safety (ARIES) examined the association between exposure to bevacizumab after disease progression (PD) and postprogression survival (PPS) in bevacizumab‐exposed metastatic colorectal cancer (mCRC) through the application of time‐dependent and time‐fixed analytical methods.MethodsPatients with mCRC who were treated with first‐line bevacizumab and who survived first PD (PD1) were included. A time‐dependent Cox regression model was fitted to assess the effect of cumulative bevacizumab exposure on PPS, while controlling for potential confounders. In addition to support findings from previous studies, a modified intent‐to‐treat (mITT) analysis compared PPS in patients who received bevacizumab beyond disease progression (BBP) with those who did not (No‐BBP).ResultsOf 1550 patients, 1199 survived PD1 and had a median PPS of 13.4 months. Cumulative bevacizumab exposure was associated with improved PPS (p = 0.0040). After adjusting for confounders, the hazard ratios (HRs) for PPS decreased, on average, by 1.2% (range, 1.1–1.3%) with each additional dose of bevacizumab. In the mITT analysis, the median PPS for BBP (n = 438) was 14.4 months vs 10.6 months with for No‐BBP (n = 667). BBP was found to be independently associated with longer PPS in a multivariable Cox regression analysis (HR, 0.84; 95% confidence interval, 0.73–0.97). Protocol‐specified adverse events suspected to be associated with bevacizumab occurred in 13.0% of patients with BBP.ConclusionThis analysis supports the observation that bevacizumab exposure after PD1 is associated with longer PPS in mCRC. Copyright © 2014 John Wiley & Sons, Ltd.
Neural Autoantibody Clusters Aid Diagnosis of Cancer
Horta, Erika , Lennon, Vanda A. , Jenkins, Sarah M. , McKeon, Andrew , Klein, Christopher J. , Pittock, Sean J. , Smith, Carin Y. , Lachance, Daniel Honore , Pittock, S J , Klein, Christopher J , McKeon, Andrew

Mayo Clinic

Clinical Cancer Research | May 16, 2014 | Volume: 20 | Issue: 14 | Pages: 3862-3869

10.1158/1078-0432.ccr-14-0652 | PMID 24833664 Get It

Abstract Purpose: Clustering of neural autoantibodies in patients with paraneoplastic neurologic disorders may predict tumor type. A mathematical analysis of neural autoantibody clusters was performed in 78,889 patients undergoing evaluation for a suspected paraneoplastic autoimmune neurologic disorder. Tumor predictive autoantibody profiles were confirmed in sera from patients with histologically proven tonsillar cancer, thymoma, and lung cancer. Patients and Methods: Of note, 78,889 patient sera were tested for 15 defined neural autoantibodies (1.2 million tests). The observed and hypothesized frequencies of autoantibody clusters were compared and their tumor associations defined. A tumor validation study comprised serum from 368 patients with a variety of tumors (thymoma, lung, or tonsil). Results: Informative oncological associations included (i) thymoma in 85% of patients with muscle striational, acetylcholine receptor antibodies plus CRMP5 autoantibodies; (ii) lung carcinoma in 80% with both P/Q-type and N-type calcium channel antibodies plus SOX1-IgG; and (iii) in men, prostate carcinoma frequency more than doubled when striational and muscle AChR specificities were accompanied by ganglionic AChR antibody. In women, amphiphysin-IgG alone was associated commonly with breast carcinoma, but amphiphysin-IgG, coexisting with antineuronal nuclear autoantibody-type 1 or CRMP5-IgG, was associated with lung cancer (P &lt; 0.0001). In the validation cohorts, many tumor-associated profiles were encountered that matched the clusters identified in the screening study (e.g., 15% of thymoma patients had striational, acetylcholine receptor antibodies plus collapsin response-mediator protein-5 autoantibodies). Conclusions: Neural autoantibodies commonly coexist in specific clusters that are identifiable by comprehensive screening. Signature autoantibody clusters may predict a patient's cancer risk and type. Clin Cancer Res; 20(14); 3862–9. ©2014 AACR.
Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline
Ramakrishna, Naren , Temin, Sarah , Chandarlapaty, Sarat , Crews, Jennie R. , Davidson, Nancy E. , Esteva, Francisco J. , Giordano, Sharon H. , González-Angulo, Ana M. , Kirshner, Jeffrey J., Krop, Ian E. , Levinson, Jennifer, Modi, Shanu , Patt, Debra A. , Perez, Edith A. , Perlmutter, Jane , Krop, Ian, Winer, Eric P. , Lin, Nancy U. , Modi, Shanu

Mayo Clinic

Journal of Clinical Oncology | May 6, 2014 | Volume: 32 | Issue: 19 | Pages: 2100-2108

10.1200/jco.2013.54.0955 | PMID 24799487 Get It

Purpose To provide formal expert consensus–based recommendations to practicing oncologists and others on the management of brain metastases for patients with human epidermal growth factor receptor 2 (HER2) –positive advanced breast cancer. Methods The American Society of Clinical Oncology (ASCO) convened a panel of medical oncology, radiation oncology, guideline implementation, and advocacy experts and conducted a systematic review of the literature. When that failed to yield sufficiently strong quality evidence, the Expert Panel undertook a formal expert consensus–based process to produce these recommendations. ASCO used a modified Delphi process. The panel members drafted recommendations, and a group of other experts joined them for two rounds of formal ratings of the recommendations. Results No studies or existing guidelines met the systematic review criteria; therefore, ASCO conducted a formal expert consensus–based process. Recommendations Patients with brain metastases should receive appropriate local therapy and systemic therapy, if indicated. Local therapies include surgery, whole-brain radiotherapy, and stereotactic radiosurgery. Treatments depend on factors such as patient prognosis, presence of symptoms, resectability, number and size of metastases, prior therapy, and whether metastases are diffuse. Other options include systemic therapy, best supportive care, enrollment onto a clinical trial, and/or palliative care. Clinicians should not perform routine magnetic resonance imaging (MRI) to screen for brain metastases, but rather should have a low threshold for MRI of the brain because of the high incidence of brain metastases among patients with HER2-positive advanced breast cancer.
Turkey Versus Guinea Pig Red Blood Cells: Hemagglutination Differences Alter Hemagglutination Inhibition Responses Against Influenza A/H1N1
Ovsyannikova, Inna G. , White, Sarah J., Albrecht, Randy A. , García‐Sastre, Adolfo , Poland, Gregory A. , García-Sastre, Adolfo

Mayo Clinic

Viral Immunology | April 30, 2014 | Volume: 27 | Issue: 4 | Pages: 174-178

10.1089/vim.2013.0111 | PMID 24787023 Get It

For influenza hemagglutination inhibition (HAI) assays, species selection of red blood cells (RBCs) is critical to determine antibody titers to influenza viruses reliably. We compared pandemic influenza virus A/H1N1 (pdH1N1) HAI titers using turkey or guinea pig RBCs. Turkey RBCs appear to be the more appropriate species choice for influenza A/pH1N1 HAI assays.
Glycoprotein 120 Binding to CXCR4 Causes p38-Dependent Primary T Cell Death That Is Facilitated by, but Does Not Require Cell-Associated CD4
Trushin, Sergey A., Algeciras-Schimnich, Alicia , Vlahakis, Stacey R., Bren, Gary D., Warren, Sarah, Schnepple, David, Badley, Andrew D. , Badley, Andrew D

Mayo Clinic

The Journal of Immunology | April 18, 2014 | Volume: 178 | Issue: 8 | Pages: 4846-4853

10.4049/jimmunol.178.8.4846 | PMID 17404265 Get It

Abstract HIV-1 infection causes the depletion of host CD4 T cells through direct and indirect (bystander) mechanisms. Although HIV Env has been implicated in apoptosis of uninfected CD4 T cells via gp120 binding to either CD4 and/or the chemokine receptor 4 (CXCR4), conflicting data exist concerning the molecular mechanisms involved. Using primary human CD4 T cells, we demonstrate that gp120 binding to CD4 T cells activates proapoptotic p38, but does not activate antiapoptotic Akt. Because ligation of the CD4 receptor alone or the CXCR4 receptor alone causes p38 activation and apoptosis, we used the soluble inhibitors, soluble CD4 (sCD4) or AMD3100, to delineate the role of CD4 and CXCR4 receptors, respectively, in gp120-induced p38 activation and death. sCD4 alone augments gp120-induced death, suggesting that CXCR4 signaling is principally responsible. Supporting that model, AMD3100 reduces death caused by gp120 or by gp120/sCD4. Finally, prevention of gp120-CXCR4 interaction with 12G5 Abs blocks p38 activation and apoptosis, whereas inhibition of CD4-gp120 interaction with Leu-3a has no effect. Consequently, we conclude that gp120 interaction with CXCR4 is required for gp120 apoptotic effects in primary human T cells.
Envelope Type and Response Rates in a Survey of Health Professionals
Tilburt, Jon C. , Lackore, Kandace A. , Jenkins, Sarah M. , James, Katherine M. , Beebe, Timothy J. , Ziegenfuss, Jeanette Y. , Beebe, Timothy J.

Mayo Clinic

Field Methods | April 8, 2014 | Volume: 26 | Issue: 4 | Pages: 380-389

10.1177/1525822x14527726 Get It

Surveys are an important tool for assessing physician and nursing professionals’ practice patterns and guideline adherence. Obtaining quality survey data consisting of low item and unit nonresponse remains a persistent challenge in these populations. We tested the relative impact of two envelope types (padded vs. priority mail) on unit and item nonresponse in a survey of Minnesota health care workers. Respondents were randomized to receive a survey in one of two envelope types: a padded 8.5′′ × 11′′ envelope or a similarly sized priority mail envelope. After the first mailing, the response rate was 53.9% and did not differ across envelope conditions. Females and RNs were more likely to respond to the priority envelope than the padded envelope, but this finding did not hold in multivariate analysis. There was no difference in item nonresponse across the two envelope conditions. It may be that our two approaches were not enough to permeate the semi-porous membrane of gatekeeping that has been posited as a driver of low physician survey response rates relative to those observed in the general population. Nonetheless, our findings suggest that packaging may matter for some populations and not others.